Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway.

He J, Shi J, Xu X, Zhang W, Wang Y, Chen X, Du Y, Zhu N, Zhang J, Wang Q, Yang J.

J Biosci. 2012 Jun;37(2):243-57.

2.

SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function.

Giacomelli M, Tamassia N, Moratto D, Bertolini P, Ricci G, Bertulli C, Plebani A, Cassatella M, Bazzoni F, Badolato R.

Eur J Immunol. 2011 Oct;41(10):3075-84. doi: 10.1002/eji.201141721. Epub 2011 Sep 6.

3.

Clinical features, STAT3 gene mutations and Th17 cell analysis in nine children with hyper-IgE syndrome in mainland China.

Zhang LY, Tian W, Shu L, Jiang LP, Zhan YZ, Liu W, Zhao XD, Cui YX, Tang XM, Wang M, Wu DQ, Yang XQ.

Scand J Immunol. 2013 Sep;78(3):258-65. doi: 10.1111/sji.12063.

4.

Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups.

Jiao H, Tóth B, Erdos M, Fransson I, Rákóczi E, Balogh I, Magyarics Z, Dérfalvi B, Csorba G, Szaflarska A, Megarbane A, Akatcherian C, Dbaibo G, Rajnavölgyi E, Hammarström L, Kere J, Lefranc G, Maródi L.

Mol Immunol. 2008 Nov;46(1):202-6. doi: 10.1016/j.molimm.2008.07.001. Epub 2008 Aug 15.

PMID:
18706697
5.

Hyper-IgE syndrome.

Minegishi Y.

Curr Opin Immunol. 2009 Oct;21(5):487-92. doi: 10.1016/j.coi.2009.07.013. Epub 2009 Aug 28. Review.

PMID:
19717292
6.

Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome.

Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, Metin A, Karasuyama H.

Nature. 2007 Aug 30;448(7157):1058-62. Epub 2007 Aug 5.

PMID:
17676033
7.

Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.

Minegishi Y, Karasuyama H.

Int Immunol. 2009 Feb;21(2):105-12. doi: 10.1093/intimm/dxn134. Epub 2008 Dec 15. Review.

8.

A novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene, in hyper-IgE syndrome.

Papanastasiou AD, Mantagos S, Papanastasiou DA, Zarkadis IK.

Mol Immunol. 2010 Apr;47(7-8):1629-34. doi: 10.1016/j.molimm.2010.01.010. Epub 2010 Feb 9.

PMID:
20149460
9.

Clinical aspects and genetic analysis of Taiwanese patients with the phenotype of hyper-immunoglobulin E recurrent infection syndromes (HIES).

Lee WI, Huang JL, Lin SJ, Yeh KW, Chen LC, Hsieh MY, Huang YC, Kuo HC, Yang KD, Yu HR, Jaing TH, Yang CH.

J Clin Immunol. 2011 Apr;31(2):272-80. doi: 10.1007/s10875-010-9479-1. Epub 2010 Dec 1.

PMID:
21120687
10.

Clinical, immunological and genetic features in Taiwanese patients with the phenotype of hyper-immunoglobulin E recurrent infection syndromes (HIES).

Lee WI, Huang JL, Lin SJ, Yeh KW, Chen LC, Ou LS, Yao TC, Hsieh MY, Huang YC, Yu HR, Kuo HC, Yang KD, Jaing TH.

Immunobiology. 2011 Aug;216(8):909-17. doi: 10.1016/j.imbio.2011.01.008. Epub 2011 Jan 18.

PMID:
21324546
11.

Genetic origins of hyper-IgE syndrome.

Minegishi Y, Karasuyama H.

Curr Allergy Asthma Rep. 2008 Sep;8(5):386-91.

PMID:
18682102
12.

Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells.

Saito M, Nagasawa M, Takada H, Hara T, Tsuchiya S, Agematsu K, Yamada M, Kawamura N, Ariga T, Tsuge I, Nonoyama S, Karasuyama H, Minegishi Y.

J Exp Med. 2011 Feb 14;208(2):235-49. doi: 10.1084/jem.20100799. Epub 2011 Feb 7.

13.

Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome.

Minegishi Y, Saito M.

Ann N Y Acad Sci. 2011 Dec;1246:34-40. doi: 10.1111/j.1749-6632.2011.06280.x. Review.

PMID:
22236428
14.

Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome.

Al Khatib S, Keles S, Garcia-Lloret M, Karakoc-Aydiner E, Reisli I, Artac H, Camcioglu Y, Cokugras H, Somer A, Kutukculer N, Yilmaz M, Ikinciogullari A, Yegin O, Yüksek M, Genel F, Kucukosmanoglu E, Baki A, Bahceciler NN, Rambhatla A, Nickerson DW, McGhee S, Barlan IB, Chatila T.

J Allergy Clin Immunol. 2009 Aug;124(2):342-8, 348.e1-5. doi: 10.1016/j.jaci.2009.05.004. Epub 2009 Jul 3.

15.

STAT3 signaling and the hyper-IgE syndrome.

Levy DE, Loomis CA.

N Engl J Med. 2007 Oct 18;357(16):1655-8. Epub 2007 Sep 19. No abstract available.

PMID:
17881746
16.

Blood CD4+CD45RO+CXCR5+ T cells are decreased but partially functional in signal transducer and activator of transcription 3 deficiency.

Mazerolles F, Picard C, Kracker S, Fischer A, Durandy A.

J Allergy Clin Immunol. 2013 Apr;131(4):1146-56, 1156.e1-5. doi: 10.1016/j.jaci.2012.12.1519. Epub 2013 Feb 10.

PMID:
23403044
17.

[STAT3 mutation identified in patients with Hyper-IgE syndrome].

Picard C.

Med Sci (Paris). 2008 Mar;24(3):242-3. doi: 10.1051/medsci/2008243242. French. No abstract available.

18.

Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.

Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, Zhu Q, Jansson AF, Barboza J, Schimke LF, Leppert MF, Getz MM, Seger RA, Hill HR, Belohradsky BH, Torgerson TR, Ochs HD.

J Allergy Clin Immunol. 2008 Jul;122(1):181-7. doi: 10.1016/j.jaci.2008.04.037.

19.

Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease.

Horváth R, Rožková D, Lašťovička J, Poloučková A, Sedláček P, Sedivá A, Spíšek R.

Clin Exp Immunol. 2011 Oct;166(1):26-33. doi: 10.1111/j.1365-2249.2011.04449.x.

20.

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.

Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G, Poussin K, Zucman-Rossi J.

J Exp Med. 2011 Jul 4;208(7):1359-66. doi: 10.1084/jem.20110283. Epub 2011 Jun 20.

Items per page

Supplemental Content

Write to the Help Desk